R&D channel feed – Endpoints News

R&D channel feed

Affimed spurs promising response numbers in NK cell study, but durability will be the big question

4 years ago

Bluebird bio may finally get a gene therapy approved in the US

4 years ago

Bouncing back from a PhII flop in schizophrenia, Neurocrine steers into the busy M4/M1 pathway with a $100M cash deal

4 years ago

FDA delays its decision on Bristol Myers' $13B heart drug another three months

4 years ago

Connect Biopharma celebrates a mid-stage win for its Dupixent rival, but shares tank after investors clamor for data

4 years ago

Daiichi Sankyo looks to bring FLT3 drug back from the dead with late-stage win in early AML patients

4 years ago

As J&J moves to split its business, execs lay out future R&D focus — and tout megablockbuster potential

4 years ago

Safety threat forces Enanta to scrap HBV trials — sending discovery team back to drawing board

4 years ago

Merck hits the brakes on development program as safety fears trigger alarm

4 years ago

Passive vaccination? AstraZeneca spotlights six-month protection with Covid-19 antibody among vulnerable group

4 years ago

Cassava's problems just got much worse as SEC launches probe into data manipulation claims — report

4 years ago

CRISPR, ViaCyte beat Vertex to the clinic with diabetes cell therapy that evades the immune system

4 years ago

Out to prove the next big I/O target, Immunitas' chief dealmaker steps up to CEO role

4 years ago

'I bleed Biogen': Just months after the big biotech was slammed following the controversial OK of aducanumab, R&D chief Al Sandrock makes an abrupt exit

4 years ago

Eyeing an accelerated BLA, PhaseBio says its monoclonal antibody reversed the dangerous effects of AstraZeneca's blood thinner

4 years ago

Bristol Myers and Janssen race toward PhIII with a next-gen blood thinner

4 years ago

AstraZeneca, Moderna start to raise the curtain on a new mRNA heart drug — but efficacy will have to wait

4 years ago

Merck looks to ditch the needles with its next-gen oral PCSK9 inhibitor for high cholesterol

4 years ago

Reeling from PD-1 slapdown, Incyte stirs concerns with side effects of oral PD-L1 — although drug is also 'clearly active'

4 years ago

Eli Lilly and Boehringer Ingelheim set their sights on acute heart failure with new Jardiance data

4 years ago

J&J looks to toss its SGLT2 hat in the ring for two types of heart failure

4 years ago

A couple months ahead of its PDUFA date, Bristol Myers rolls out long-term data for mavacamten

4 years ago

Spurned by FDA on another immunotherapy, Agenus holds up early data for CTLA-4 drug across tumor types

4 years ago

AstraZeneca expects 'modest profitability' for next round of Covid-19 vaccine supply deals — and prunes pipeline in Q3 update

4 years ago

First page Previous page 153 154 155156157 158 159 Next page Last page